Sunday 18 October 2026
Export ATOS’s income statement to Excel — free account
Atossa Therapeutics, Inc.
ATOS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 9.48% and free cash flow fell 32.9%, each against the same quarter a year earlier.
2.91
0.26
+9.81%
Follow ATOS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 234.00 | 39.60 | 12.00 | 14.85 | 11.40 | 13.20 | 7.50 | 8.25 | 11.55 | 8.25 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 1,917.00 | 333.00 | 160.20 | 110.85 | 76.20 | 147.00 | 27.00 | 20.85 | 34.65 | 19.35 | |||||
| People | |||||||||||||||
| People | Employees | 6 | 7 | 6 | 6 | 8 | 8 | 11 | 10 | 13 | 14 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (6) | (8) | (11) | (17) | (18) | (21) | (27) | (30) | (26) | (35) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (6) | (8) | (11) | (17) | (18) | (21) | (27) | (30) | (26) | (35) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (388.97) | (97.98) | (82.46) | (30.43) | (29.53) | (2.70) | (3.15) | (3.60) | (3.00) | (4.04) | |||||
| Cash flow | (327.72) | (101.45) | (32.32) | (16.11) | (15.34) | (2.11) | (2.46) | (2.49) | (2.51) | (3.46) | |||||
| Capex | (0.56) | 0.00 | (0.40) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (328.28) | (101.45) | (32.72) | (16.12) | (15.35) | (2.11) | (2.46) | (2.49) | (2.51) | (3.46) | |||||
| Book value | 188.85 | 106.75 | 31.75 | 23.22 | 36.02 | 17.71 | 13.97 | 10.82 | 8.52 | 4.57 | |||||
| Shares, m | 0 | 0 | 0 | 1 | 1 | 8 | 8 | 8 | 8 | 9 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (5) | (7) | (9) | (9) | (12) | (16) | (21) | (21) | (21) | (30) | ||||
| Capex | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | (5) | (7) | (9) | (9) | (12) | (16) | (21) | (21) | (21) | (30) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 2 | 7 | 9 | 13 | 27 | 138 | 113 | 87 | 69 | 37 | ||||
| Total debt | — | — | — | 0 | 0 | — | — | — | — | — | |||||
| Net debt | (3) | (7) | (10) | (13) | (40) | (136) | (111) | (89) | (71) | (41) | |||||
| Shareholders’ equity | 3 | 7 | 9 | 13 | 27 | 138 | 118 | 91 | 71 | 39 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (122.62) | (173.71) | (230.17) | (131.55) | (77.90) | (22.39) | (20.36) | (27.39) | (29.54) | (56.06) | ||||
| ROIC | (35,321.81) | 0.00 | 0.00 | (2,321.12) | 0.00 | (777.78) | (248.52) | (801.74) | (6,100.04) | 0.00 | |||||
| ROE | (186.26) | (213.05) | (342.46) | (182.33) | (114.42) | (25.11) | (21.10) | (28.80) | (31.39) | (62.74) | |||||
Negative figures in brackets.
Fiscal years to Dec 2015 · latest quarter Dec 2014 · fundamentals updated 2 Oct 2026
Charts ten years each
Atossa Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IBO Impact Biomedical Inc. | $27.0M | 0.2× | — | −57.14% (below 0%: shrinking) | n/m | +167.72% (above 0%: growing) | 66.67% | (23,400.00%) | Compare |
| ATOS Atossa Therapeutics, Inc. | $26.4M | — (loss-making) | — | −94.28% (below 0%: shrinking) | n/m | −32.86% (below 0%: shrinking) | 0.00% | 0.00% | |
| IGC IGC Pharma, Inc. | $26.3M | — (loss-making) | — (loss-making) | −19.70% (below 0%: shrinking) | n/m | −103.33% (below 0%: shrinking) | 18.11% | (1,050.57%) | Compare |
| MCRB Seres Therapeutics, Inc. | $25.2M | — (loss-making) | — (loss-making) | +96.79% (above 0%: growing) | n/m | −66.15% (below 0%: shrinking) | 100.00% | (2,890.35%) | Compare |
| ABVC ABVC BioPharma, Inc. | $24.9M | — (loss-making) | — (loss-making) | +66,233.33% (above 0%: growing) | n/m | +72.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| BYSI BeyondSpring Inc. | $23.9M | — (loss-making) | — (loss-making) | +87.78% (above 0%: growing) | n/m | +35.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CYAD Celyad SA | $23.8M | — (loss-making) | — (loss-making) | — | n/m | +78.72% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PLRZ Polyrizon Ltd. | $23.7M | — | — | — | — | −744.51% (below 0%: shrinking) | — | — | Compare |
| IMMP Prima BioMed Ltd | $23.7M | — (loss-making) | — | — | n/m | −589,653.13% (below 0%: shrinking) | 100.00% | (101.89%) | Compare |
| Median of peers | $24.4M | — | — | +87.78% | — | −15.18% | 100.00% | (101.89%) |
Atossa Therapeutics, Inc. (ATOS) key facts
- Atossa Therapeutics, Inc. (ATOS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ATOS traded at $2.91, a market capitalization of $26.4 million.
- Return on equity was −62.7% and debt-to-equity 0.00.
Atossa Therapeutics, Inc. (ATOS) Latest News
No news at this impact. Lower the threshold for more.